Daicel Corporation
Stock Price Chart
2026/08/21 UpdatedPrice Trend
2026/08/21 UpdatedPrice & Trading Details
2026/08/21 UpdatedPRICE
TRADING
Analyst Recommendations 8 analysts
Updated 2026/08/01Earnings Calendar
Updated 2026/08/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2026/07/30 | ¥22.29 | ¥36.65 | +64.4% |
| 2026/05/12 | ¥36.95 | ¥-96.24 | -360.5% |
| 2026/02/04 | ¥40.17 | ¥64.09 | +59.6% |
| 2025/11/05 | ¥57.20 | ¥34.61 | -39.5% |
Shareholder Composition
Updated 2026/08/01Major Holders
Updated 2026/08/01| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
American Century ETF Trust-Avantis International Small Cap Value ETF
|
4.9M | +3.14% | |
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
3.5M | -2.98% | |
|
T. ROWE PRICE Intl Fd.S, INC.-T. Rowe Price Intl Discovery Fd.
|
3.1M | +13.86% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
2.2M | -0.75% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
1.8M | 0.00% | |
|
Victory Portfolios-Victory Trivalent International Small-Cap Fund
|
1.7M | -0.04% |
Dividend History
Updated 2026/08/23| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥30 | -50.0% |
| 2025 | ¥60 | +9.1% |
| 2024 | ¥55 | +22.2% |
| 2023 | ¥45 | +25.0% |
| 2022 | ¥36 | - |
Financial Performance
2026/08/23 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥467,937M | ¥538,026M | ¥558,056M | ¥586,531M |
| Gross Profit | ¥138,607M | ¥145,811M | ¥159,280M | ¥164,746M |
| Operating Income | ¥50,697M | ¥47,508M | ¥62,393M | ¥61,011M |
| Pretax Income | ¥47,644M | ¥56,399M | ¥77,698M | ¥67,480M |
| Net Income | ¥31,254M | ¥40,682M | ¥55,834M | ¥49,480M |
| EPS | ¥104.14 | ¥138.87 | ¥138.87 | ¥181.44 |
| Operating Margin | 10.83% | 8.83% | 11.18% | 10.40% |
| Balance Sheet | ||||
| Total Assets | ¥698,836M | ¥765,606M | ¥839,169M | ¥813,831M |
| Total Equity | ¥272,016M | ¥295,208M | ¥359,443M | ¥359,983M |
| Total Liabilities | ¥426,820M | ¥470,398M | ¥479,726M | ¥453,848M |
| Cash | ¥88,130M | ¥93,840M | ¥73,183M | ¥65,142M |
| Interest-bearing Debt | ¥280,502M | ¥317,832M | ¥299,790M | ¥280,919M |
| Equity Ratio | 38.92% | 38.56% | 42.83% | 44.23% |
| D/E Ratio | 1.03 | 1.08 | 0.83 | 0.78 |
| Cash Flow | ||||
| Operating CF | ¥42,993M | ¥26,847M | ¥76,729M | ¥93,406M |
| Investing CF | -¥46,528M | -¥44,093M | -¥55,374M | -¥47,869M |
| Financing CF | -¥5,452M | ¥19,956M | -¥52,373M | -¥48,855M |
| Free CF | -¥4,478M | -¥25,076M | ¥7,521M | ¥21,064M |
| Efficiency | ||||
| ROE | 11.49% | 13.78% | 15.53% | 13.75% |
| ROA | 4.47% | 5.31% | 6.65% | 6.08% |
Latest IR Information
-
Notice of Payment Completion for the Sale of Treasury Stock as Part of Restricted Stock for Employee Stock Ownership Plan and Partial Expiration
Sale of treasury stock for the employee stock ownership plan has been paid in. The number of shares sold and the total consideration have changed, and a portion expired.
Read more -
Notice on Payment Completion for the Transfer-Restricted Stock Compensation Share Buyback
Notice of payment completion for the disposal of treasury stock. Shares disposed: 118,520 shares; disposal price: 1,400.5 yen per share; total: 165,987,260 yen. Disposed to internal directors and officers; date: 2026-08-10.
Read more -
Unknown
The financial results for the first quarter of the fiscal year ending March 2027 show net sales of 152,383 million yen (up 10.0% YoY), operating income of 14,573 million yen (up 7.4%), and net income of 9,548 million yen (up...
Read more -
Fiscal Year 2027 Q1 Financial Results|Net Sales of ¥152.4 billion (YoY +9.4%)
Daicel achieved net sales of ¥152.4 billion (YoY +9.4%) and operating income of ¥14.0 billion (+7.7%) in the first quarter of fiscal year 2027. Segment-wise, the high-performance materials and materials businesses performed well, supporting overall sales and profits.
Read more
Latest News (5 items)
-
Average Analyst Rating: hold
Average Target Price: ¥1,486
Rating Score: 3.13 (Based on 8 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Daicel Corporation engages in the materials, medical/healthcare, smart, safety, and engineering plastics businesses in Japan and internationally. The company offers medical/healthcare products, including BELLOCEA S7, a spherical cellulose acetate particle; FLAVOCELL S-Equol; Urolithin A; polyglycerols; konjac ceramide; excipients for foods; chiral columns and reagents; and Actranza lab, as well as separation and analytical services. It also provides performance films, solvents for electronic materials, cycloaliphatic epoxies, polymers for photoresists, optical lenses, and caprolactone derivatives; functional films and materials used in smartphones, PCs, TVs, and in-vehicle displays, polymers and solvents used in the semiconductor manufacturing process; and lenses used in VR, smartphones and various sensors. In addition, the company offers airbags inflators, pyro-fuses, and gas generators for seat belt pretensioners; acetic acid, acetic acid derivatives, acetate tow, ketene / diketene derivatives, cellulose acetate for LCD optical films, amines, and 1,3-butylene glycol; and reverse osmosis membrane and ultrafiltration membrane products, as well as water treatment systems. Further, it provides Engineering plastics comprising polyacetal, PBT resin, polybutylene terephthalate, polyphenylene sulfide, liquid crystal polymer, and cyclic olefin copolymer; AS resin, acetate plastics, water-soluble polymers, and barrier films for packaging; ABS resins, various polymer alloys, plastic compounds; Polyamide-12 and PEEK resin; and various molded containers. The company's products are used in transportation, electronics, medical care, personal care, lifestyle, everyday life, and environment and energy applications. The company was formerly known as Daicel Chemical Industries, Ltd. and changed its name to Daicel Corporation in October 2011. Daicel Corporation was incorporated in 1919 and is headquartered in Osaka, Japan.